Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal Infliximab for Uveitic Macular Edema
NCT00958906Phase 2Withdrawn
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Aug 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of infliximab in uveitic macular edema (UME), sponsored by Icahn School of Medicine at Mount Sinai. Planned start Aug 2009; status: withdrawn.
02
Drugs
infliximab
03
Conditions
uveitic macular edema (UME)
Beyond the preview
Go deeper on NCT00958906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00958906.